期刊文献+

伊布利特治疗急性心房纤颤102例分析 被引量:1

下载PDF
导出
摘要 目的回顾性分析新型抗心律失常药物伊布利特对急性心房纤颤患者的转复疗效。方法对住院治疗的102例急性房颤患者,给予伊布利特1mg,10min内静注;作为对照组,76例急性房颤患者给予普罗帕酮70mg,10min内静注。两组注射后均观察30min,若房颤仍未终止且QTc间期<550ms,两组分别给予第2次治疗,剂量、用法与第一次相同,连续观察4h。观察房颤转复所用时间(从第一剂开始注射时算起)。结果伊布利特组有86例患者恢复窦性心律,而对照组有42例患者恢复窦性心律。统计分析发现伊布利特的转复时间明显小于普罗帕酮(P<0.01)。结论伊布利特是使房颤快速转律的有效药物,转复时间短,副作用少,临床应用可替代普罗帕酮。
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第7期1726-1727,共2页 Journal of Southern Medical University
  • 相关文献

参考文献11

  • 1杨延宗,马长生,张澍.第四届心房颤动国际论坛会议纪要[J].中华心律失常学杂志,2006,10(5):393-400. 被引量:3
  • 2Singh SN, Patrick J, Patrick J. Antiarrhythmic drugs[J]. Curr Treat Options Cardiovasc Med, 2004, 6(5): 357-64.
  • 3Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity[J].Drugs, 2008, 68(5): 607-30.
  • 4Burkart TA, Kron J, Miles WM, et al. Successful termination of atrial flutter by ibutilide during pregnancy [J]. Pacing Clin Electrophysiol, 2007, 30(2): 283-6.
  • 5Tercius AJ, Kluger J, Coleman CI, et al. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter [J]. Pacing Clin Electrophysiol, 2007, 30(11): 1331-5.
  • 6Blaauw Y, Schotten U, van Hunnik A, et al. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat[J]. Cardiovase Res, 2007, 75 (1): 89-98.
  • 7Mountantonakis SE, Moutzouris DA, Tiu RV, et al. Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter [J]. Am J Emerg Med, 2006, 24(4): 407-12.
  • 8TaUaj JA, Franco V, Rayburn BK, et al. Safety and efficacy of ibutilide in heart transplant recipients [J ]. J Heart Lung Transplant, 2009, 28(5): 505-7.
  • 9Eidher U, Freihoff F, Kaltenbrunner W, et al. Efficacy and safety of ibutilide for the conversion ofmonomorphic atrial tachycardia [J]. Pacing Clin Electrophysiol, 2006, 29(4): 358-62.
  • 10张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43

二级参考文献8

  • 1Miller MR, McNamara RL, Segal JB,et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a Meta analysis of clinical trials. J Fam Pract,2000,49:1033-1046.
  • 2Cropp Js, Antal EG, Talbert RL,et al. Ibutilide: a new class Ⅲ antiarrhythmic agent. Parmarcotherapy, 1997,17:1-9.
  • 3Lych JR, Baskin EP, Nutt EM, et al, Comparision of binding to rapidly activating delayed rectifier K channel, Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents. J Cardiovasc Pharmacol, 1995,25:336-340.
  • 4Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of Ibutilide. Am J Cardiol,1996,78(8A): 12-16.
  • 5Baskin EP , Lynch JJ Jr. Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers. Pharmacol Exp Ther, 1998,285:135-142.
  • 6Ellenbogen KA, Stambler BS, Wood MA, et al . Efficacy of intravenous Ibutilide for rapid termination of atrial fibrillation and atril flutter: a dose-response study. J Am Coll Cardiol, 1996, 28: 130-136.
  • 7Gowdw RM, Punukollu G, Khan LA, et al. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther, 2003,10: 259-263.
  • 8Kowey PR, Vanderlugt JT, Luderer JR. Safety and risk/benefit analysis of Ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol , 1996,78 (suppl 8A): 46-52.

共引文献43

同被引文献3

  • 1Mountantonakis SE, Moutzouris DA, Tiu RV, et al. Ibutilide to ex- pedite ED therapy for recent - onset atrial fibrillation flutter[ J ]. Am J Emerg Med ,2006,24(4) :407 -412.
  • 2陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:717-718.
  • 3高永红,张存泰,阮磊,李连东,全小庆,周青,徐仁德,王国强,蔡少艾,王天杰.伊布利特致尖端扭转性室性心动过速机制的研究[J].临床心血管病杂志,2010,26(5):378-381. 被引量:9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部